U.S. Markets closed

Today's Research Reports on Trending Tickers: Nektar Therapeutics and Aduro BioTech

NEW YORK, NY / ACCESSWIRE / December 19, 2018 / U.S. markets finished modestly higher on a very volatile trading day on Tuesday. The volatility was probably due to the market’s anxiety over the uncertainty in U.S.-China trade relation, growing fears of a government shutdown, a slide in oil prices and fears of the Federal Reserve’s tightening of monetary policy. The Dow Jones Industrial Average gained 0.35 percent to close at 23,675.64, while the S&P 500 Index increased 0.01 percent to close at 2,546.16. The Nasdaq Composite Index climbed 0.45 percent to close at 6,783.91.

The Chief Investment Strategist of Key Private Bank, Bruce McCain said, "I think it's anxiety about slowing economic growth and [traders] want assurance that someone's going to do something."

"Clearly, it's a time of uncertainly both here and overseas, but given the strength of the economy, it's going to take some time until the economic backdrop supports a bear market. It's about managing your anxiety and waiting long enough to find out that, hopefully, the news isn't so bad," he added.

The Market Edge Initiates Coverage on:

Nektar Therapeutics
https://marketedgereport.com/report/NKTR/

Aduro BioTech, Inc.
https://marketedgereport.com/report/ADRO/

Nektar Therapeutics' stock jumped 4.63% Tuesday, to close the day at $35.74. The stock recorded a trading volume of 3,534,766 shares, which was above its three months average volume of 2,485,064 shares. In the last year, Nektar Therapeutics' shares have traded in a range of 33.50 - 111.36. The share price has gained 6.69% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $37.79 is below its 200-day moving average of $50.59. Shares of the company are trading at a Price to Earnings ratio of 8.34. Shares of Nektar Therapeutics have fallen roughly 6.51 percent in the past month and are down 40.15 percent year-to-date.

Access The Market Edge's Nektar Therapeutics Research Report:
https://marketedgereport.com/report/NKTR/

On Tuesday, shares of Aduro BioTech recorded a trading volume of 1,451,449 shares, which was above the three months average volume of 721,207 shares. The stock ended the day 6.08% lower at $2.47. The share price has fallen 75.13% from its 52 week high with a 52 week trading range of 2.42 - 9.93. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $3.28 is below its 200-day moving average of $5.71. Shares of Aduro BioTech have fallen roughly 24.7 percent in the past month and are down 67.07 percent year-to-date.

Access The Market Edge's Aduro BioTech, Inc. Research Report:
https://marketedgereport.com/report/ADRO/

Our Actionable Research on Nektar Therapeutics (NASDAQ:NKTR) and Aduro BioTech, Inc. (NASDAQ:ADRO) can be downloaded free of charge at The Market Edge.

The Market Edge

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@marketedgereport.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: The Market Edge